# Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
Canonical URL: https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-multiple-presentations-from-across-its-late-stage-neurometabolic-portfolio-at-ssiem-2024
Ticker: ORTX
Company: Orchard Therapeutics
Source: Orchard Therapeutics
Published: 2024-08-28 11:01 EST
Original Source URL: https://ir.orchard-tx.com
## Summary

LONDON and BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced nine presentations from across its late-stage neurometabolic hematopoietic stem

## Article Body
LONDON and BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced nine presentations from across its late-stage neurometabolic hematopoietic stem
## Recent Company News
- 2025-12-16 17:15 EST — [Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-celebrates-addition-of-metachromatic-leukodystrophy-to-the-u-s-recommended-uniform-screening-panel) — Source: Orchard Therapeutics
- 2025-10-28 06:00 EST — [Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan](https://biopharmsignal.com/news/ORTX/kyowa-kirin-and-orchard-therapeutics-announce-otl-200-granted-orphan-regenerative-medicine-product-designation-for-early-onset-mld-in-japan) — Source: Orchard Therapeutics
- 2025-07-07 11:00 EST — [Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-last-patient-treated-in-registrational-trial-of-otl-203-for-mps-i-hurler-syndrome) — Source: Orchard Therapeutics
- 2025-05-13 11:01 EST — [Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-announces-new-england-journal-of-medicine-publication-of-long-term-clinical-outcomes-from-its-hsc-gene-therapy-for-mld-and-multiple-presentations-at-asgct-2025) — Source: Orchard Therapeutics
- 2025-02-12 12:01 EST — [Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD](https://biopharmsignal.com/news/ORTX/orchard-therapeutics-appoints-robin-kenselaar-to-chief-commercial-officer-and-announces-multiple-business-updates-pertaining-to-its-approved-hsc-gene-therapy-for-mld) — Source: Orchard Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)